{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:46:50Z","timestamp":1780105610666,"version":"3.54.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"},{"start":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T00:00:00Z","timestamp":1291680000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The pharmacological chaperones therapy is a promising approach to cure genetic diseases. It relies on substrate competitors used at sub-inhibitory concentration which can be administered orally, reach difficult tissues and have low cost. Clinical trials are currently carried out for Fabry disease, a lysosomal storage disorder caused by inherited genetic mutations of alpha-galactosidase. Regrettably, not all genotypes respond to these drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We collected the experimental data available in literature on the enzymatic activity of ninety-six missense mutants of lysosomal alpha-galactosidase measured in the presence of pharmacological chaperones. We associated with each mutation seven features derived from the analysis of 3D-structure of the enzyme, two features associated with their thermo-dynamic stability and four features derived from sequence alone. Structural and thermodynamic analysis explains why some mutants of human lysosomal alpha-galactosidase cannot be rescued by pharmacological chaperones: approximately forty per cent of the non responsive cases examined can be correctly associated with a negative prognostic feature. They include mutations occurring in the active site pocket, mutations preventing disulphide bridge formation and severely destabilising mutations. Despite this finding, prediction of mutations responsive to pharmacological chaperones cannot be achieved with high accuracy relying on combinations of structure- and thermodynamic-derived features even with the aid of classical and state of the art statistical learning methods.<\/jats:p><jats:p>We developed a procedure to predict responsive mutations with an accuracy as high as 87%: the method scores the mutations by using a suitable position-specific substitution matrix. Our approach is of general applicability since it does not require the knowledge of 3D-structure but relies only on the sequence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Responsiveness to pharmacological chaperones depends on the structural\/functional features of the disease-associated protein, whose complex interplay is best reflected on sequence conservation by evolutionary pressure. We propose a predictive method which can be applied to screen novel mutations of alpha galactosidase. The same approach can be extended on a genomic scale to find candidates for therapy with pharmacological chaperones among proteins with unknown tertiary structures.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1750-1172-5-36","type":"journal-article","created":{"date-parts":[[2010,12,7]],"date-time":"2010-12-07T19:14:01Z","timestamp":1291749241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study"],"prefix":"10.1186","volume":"5","author":[{"given":"Giuseppina","family":"Andreotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario R","family":"Guarracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cammisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Correra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Cubellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,12,7]]},"reference":[{"key":"199_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/4801","volume":"5","author":"JQ Fan","year":"1999","unstructured":"Fan JQ, Ishii S, Asano N, Suzuki Y: Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999, 5: 112-5. 10.1038\/4801.","journal-title":"Nat Med"},{"key":"199_CR2","doi-asserted-by":"crossref","unstructured":"Khanna R, Benjamin ER, Pellegrino L, Schilling A, Rigat BA, Soska R, Nafar H, Ranes BE, Feng J, Lun Y: The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. Febs J. 277: 1618-38. 10.1111\/j.1742-4658.2010.07588.x.","DOI":"10.1111\/j.1742-4658.2010.07588.x"},{"key":"199_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/humu.21121","volume":"30","author":"JJ Flanagan","year":"2009","unstructured":"Flanagan JJ, Rossi B, Tang K, Wu X, Mascioli K, Donaudy F, Tuzzi MR, Fontana F, Cubellis MV, Porto C, et al: The pharmacological chaperone 1-deoxynojirimycin increases the activity and lysosomal trafficking of multiple mutant forms of acid alpha-glucosidase. Hum Mutat. 2009, 30: 1683-92. 10.1002\/humu.21121.","journal-title":"Hum Mutat"},{"key":"199_CR4","doi-asserted-by":"publisher","first-page":"13478","DOI":"10.1074\/jbc.M308523200","volume":"279","author":"MB Tropak","year":"2004","unstructured":"Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D: Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem. 2004, 279: 13478-87. 10.1074\/jbc.M308523200.","journal-title":"J Biol Chem"},{"key":"199_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ejpn.2008.03.004","volume":"13","author":"A Caciotti","year":"2009","unstructured":"Caciotti A, Donati MA, d'Azzo A, Salvioli R, Guerrini R, Zammarchi E, Morrone A: The potential action of galactose as a \"chemical chaperone\": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient. Eur J Paediatr Neurol. 2009, 13: 160-4. 10.1016\/j.ejpn.2008.03.004.","journal-title":"Eur J Paediatr Neurol"},{"key":"199_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00018-008-7470-2","volume":"65","author":"Y Suzuki","year":"2008","unstructured":"Suzuki Y: Chemical chaperone therapy for GM1-gangliosidosis. Cell Mol Life Sci. 2008, 65: 351-3. 10.1007\/s00018-008-7470-2.","journal-title":"Cell Mol Life Sci"},{"key":"199_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/emmm.200900036","volume":"1","author":"G Parenti","year":"2009","unstructured":"Parenti G: Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med. 2009, 1: 268-79. 10.1002\/emmm.200900036.","journal-title":"EMBO Mol Med"},{"key":"199_CR8","doi-asserted-by":"crossref","unstructured":"Beck M, Beck M: Therapy for lysosomal storage disorders. IUBMB Life. 62: 33-40.","DOI":"10.1002\/iub.284"},{"key":"199_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S1462399407000361","volume":"9","author":"TW Loo","year":"2007","unstructured":"Loo TW, Clarke DM: Chemical and pharmacological chaperones as new therapeutic agents. Expert Rev Mol Med. 2007, 9: 1-18. 10.1017\/S1462399407000361.","journal-title":"Expert Rev Mol Med"},{"key":"199_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/BC.2008.009","volume":"389","author":"JQ Fan","year":"2008","unstructured":"Fan JQ: A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem. 2008, 389: 1-11. 10.1515\/BC.2008.009.","journal-title":"Biol Chem"},{"key":"199_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/08035320510031045","volume":"94","author":"E Schaefer","year":"2005","unstructured":"Schaefer E, Mehta A, Gal A: Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr Suppl. 2005, 94: 87-92. 10.1080\/08035320510031045. discussion 79","journal-title":"Acta Paediatr Suppl"},{"key":"199_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1086\/504601","volume":"79","author":"M Spada","year":"2006","unstructured":"Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ: High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006, 79: 31-40. 10.1086\/504601.","journal-title":"Am J Hum Genet"},{"key":"199_CR13","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","volume":"32","author":"ER Benjamin","year":"2009","unstructured":"Benjamin ER, Flanagan JJ, Schilling A, Chang HH, Agarwal L, Katz E, Wu X, Pine C, Wustman B, Desnick RJ, et al: The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines. J Inherit Metab Dis. 2009, 32: 424-40. 10.1007\/s10545-009-1077-0.","journal-title":"J Inherit Metab Dis"},{"key":"199_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/FPC.0b013e32830500f4","volume":"18","author":"SH Shin","year":"2008","unstructured":"Shin SH, Kluepfel-Stahl S, Cooney AM, Kaneski CR, Quirk JM, Schiffmann R, Brady RO, Murray GJ: Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone. Pharmacogenet Genomics. 2008, 18: 773-80. 10.1097\/FPC.0b013e32830500f4.","journal-title":"Pharmacogenet Genomics"},{"key":"199_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/humu.9520","volume":"29","author":"M Shimotori","year":"2008","unstructured":"Shimotori M, Maruyama H, Nakamura G, Suyama T, Sakamoto F, Itoh M, Miyabayashi S, Ohnishi T, Sakai N, Wataya-Kaneda M, et al: Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone. Hum Mutat. 2008, 29: 331-10.1002\/humu.9520.","journal-title":"Hum Mutat"},{"key":"199_CR16","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","volume":"50","author":"L Monserrat","year":"2007","unstructured":"Monserrat L, Gimeno-Blanes JR, Marin F, Hermida-Prieto M, Garcia-Honrubia A, Perez I, Fernandez X, de Nicolas R, de la Morena G, Paya E, et al: Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007, 50: 2399-403. 10.1016\/j.jacc.2007.06.062.","journal-title":"J Am Coll Cardiol"},{"key":"199_CR17","doi-asserted-by":"publisher","first-page":"W116","DOI":"10.1093\/nar\/gkl282","volume":"34","author":"J Dundas","year":"2006","unstructured":"Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J: CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 2006, 34: W116-8. 10.1093\/nar\/gkl282.","journal-title":"Nucleic Acids Res"},{"key":"199_CR18","unstructured":"CASTP: [http:\/\/sts.bioengr.uic.edu\/castp\/index.php]"},{"key":"199_CR19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","volume":"337","author":"SC Garman","year":"2004","unstructured":"Garman SC, Garboczi DN: The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol. 2004, 337: 319-35. 10.1016\/j.jmb.2004.01.035.","journal-title":"J Mol Biol"},{"key":"199_CR20","doi-asserted-by":"crossref","unstructured":"Guce AI, Clark NE, Salgado EN, Ivanen DR, Kulminskaya AA, Brumer H, Garman SC: Catalytic mechanism of human alpha-galactosidase. J Biol Chem. 285: 3625-32. 10.1074\/jbc.M109.060145.","DOI":"10.1074\/jbc.M109.060145"},{"key":"199_CR21","doi-asserted-by":"publisher","first-page":"4816","DOI":"10.1021\/bi9002265","volume":"48","author":"RL Lieberman","year":"2009","unstructured":"Lieberman RL, D'Aquino J A, Ringe D, Petsko GA: Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry. 2009, 48: 4816-27. 10.1021\/bi9002265.","journal-title":"Biochemistry"},{"key":"199_CR22","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","volume":"1690","author":"S Ishii","year":"2004","unstructured":"Ishii S, Yoshioka H, Mannen K, Kulkarni AB, Fan JQ: Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta. 2004, 1690: 250-7.","journal-title":"Biochim Biophys Acta"},{"key":"199_CR23","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/prot.10484","volume":"53","author":"JM Petock","year":"2003","unstructured":"Petock JM, Torshin IY, Weber IT, Harrison RW: Analysis of protein structures reveals regions of rare backbone conformation at functional sites. Proteins. 2003, 53: 872-9. 10.1002\/prot.10484.","journal-title":"Proteins"},{"key":"199_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/prot.20327","volume":"58","author":"MV Cubellis","year":"2005","unstructured":"Cubellis MV, Caillez F, Blundell TL, Lovell SC: Properties of polyproline II, a secondary structure element implicated in protein-protein interactions. Proteins. 2005, 58: 880-92. 10.1002\/prot.20327.","journal-title":"Proteins"},{"key":"199_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1142\/S0219720007003120","volume":"5","author":"CL Worth","year":"2007","unstructured":"Worth CL, Bickerton GR, Schreyer A, Forman JR, Cheng TM, Lee S, Gong S, Burke DF, Blundell TL: A structural bioinformatics approach to the analysis of nonsynonymous single nucleotide polymorphisms (nsSNPs) and their relation to disease. J Bioinform Comput Biol. 2007, 5: 1297-318. 10.1142\/S0219720007003120.","journal-title":"J Bioinform Comput Biol"},{"key":"199_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/protein\/10.1.7","volume":"10","author":"CM Topham","year":"1997","unstructured":"Topham CM, Srinivasan N, Blundell TL: Prediction of the stability of protein mutants based on structural environment-dependent amino acid substitution and propensity tables. Protein Eng. 1997, 10: 7-21. 10.1093\/protein\/10.1.7.","journal-title":"Protein Eng"},{"key":"199_CR27","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/prot.20810","volume":"62","author":"J Cheng","year":"2006","unstructured":"Cheng J, Randall A, Baldi P: Prediction of protein stability changes for single-site mutations using support vector machines. Proteins. 2006, 62: 1125-32. 10.1002\/prot.20810.","journal-title":"Proteins"},{"key":"199_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/nar\/28.1.283","volume":"28","author":"MM Gromiha","year":"2000","unstructured":"Gromiha MM, An J, Kono H, Oobatake M, Uedaira H, Prabakaran P, Sarai A: ProTherm, version 2.0: thermodynamic database for proteins and mutants. Nucleic Acids Res. 2000, 28: 283-5. 10.1093\/nar\/28.1.283.","journal-title":"Nucleic Acids Res"},{"key":"199_CR29","unstructured":"MATLAB-Arsenal: [http:\/\/www.informedia.cs.cmu.edu\/yanrong\/MATLABArsenal\/MATLABArsenal.htm]"},{"key":"199_CR30","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","volume":"25","author":"SF Altschul","year":"1997","unstructured":"Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997, 25: 3389-402. 10.1093\/nar\/25.17.3389.","journal-title":"Nucleic Acids Res"},{"key":"199_CR31","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1093\/nar\/gkf493","volume":"30","author":"V Ramensky","year":"2002","unstructured":"Ramensky V, Bork P, Sunyaev S: Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 2002, 30: 3894-900. 10.1093\/nar\/gkf493.","journal-title":"Nucleic Acids Res"},{"key":"199_CR32","doi-asserted-by":"crossref","unstructured":"Filoni C, Caciotti A, Carraresi L, Cavicchi C, Parini R, Antuzzi D, Zampetti A, Feriozzi S, Poisetti P, Garman SC: Functional studies of new GLA gene mutations leading to conformational Fabry disease. Biochim Biophys Acta. 1802: 247-52.","DOI":"10.1016\/j.bbadis.2009.11.003"},{"key":"199_CR33","unstructured":"Solis MA, Pascual B, Bosca M, Ramos V, Carda C, Monteagudo C, Torregrosa I, Pons S, Miguel A: New mutation in female patient with renal variant of Fabry disease and HIV. J Nephrol. 23: 231-3."},{"key":"199_CR34","doi-asserted-by":"publisher","first-page":"6661","DOI":"10.1093\/nar\/19.23.6661-a","volume":"19","author":"AD Borglum","year":"1991","unstructured":"Borglum AD, Byskov A, Cubellis MV, Kruse TA: An EcoRI polymorphism for the PLAUR gene. Nucleic Acids Res. 1991, 19: 6661-10.1093\/nar\/19.23.6661-a.","journal-title":"Nucleic Acids Res"},{"key":"199_CR35","unstructured":"HGMD: [http:\/\/www.hgmd.cf.ac.uk\/ac\/index.php]"},{"issue":"Suppl 1","key":"199_CR36","first-page":"S66","volume":"47","author":"AB Mehta","year":"2009","unstructured":"Mehta AB: Anderson-Fabry disease: developments in diagnosis and treatment. Int J Clin Pharmacol Ther. 2009, 47 (Suppl 1): S66-74.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"199_CR37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1750-1172-4-21","volume":"4","author":"B Hoffmann","year":"2009","unstructured":"Hoffmann B: Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis. 2009, 4: 21-10.1186\/1750-1172-4-21.","journal-title":"Orphanet J Rare Dis"},{"key":"199_CR38","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/bioinformatics\/btm073","volume":"23","author":"RE Smith","year":"2007","unstructured":"Smith RE, Lovell SC, Burke DF, Montalvao RW, Blundell TL: Andante: reducing side-chain rotamer search space during comparative modeling using environment-specific substitution probabilities. Bioinformatics. 2007, 23: 1099-105. 10.1093\/bioinformatics\/btm073.","journal-title":"Bioinformatics"},{"key":"199_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1126\/science.6879170","volume":"221","author":"ML Connolly","year":"1983","unstructured":"Connolly ML: Solvent-accessible surfaces of proteins and nucleic acids. Science. 1983, 221: 709-13. 10.1126\/science.6879170.","journal-title":"Science"},{"issue":"Suppl 4","key":"199_CR40","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1186\/1471-2105-6-S4-S8","volume":"6","author":"MV Cubellis","year":"2005","unstructured":"Cubellis MV, Cailliez F, Lovell SC: Secondary structure assignment that accurately reflects physical and evolutionary characteristics. BMC Bioinformatics. 2005, 6 (Suppl 4): S8-10.1186\/1471-2105-6-S4-S8.","journal-title":"BMC Bioinformatics"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-5-36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/1750-1172-5-36\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-5-36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T21:36:22Z","timestamp":1712007382000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/1750-1172-5-36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["199"],"URL":"https:\/\/doi.org\/10.1186\/1750-1172-5-36","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"26 May 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"36"}}